Number of items: 2.
Cornelissen, J J; Versluis, J; Passweg, J R; van Putten, W L; Manz, M G; Maertens, J; Beverloo, H B; Valk, P J; van Marwijk, Kooy M; Wijermans, P W; Schaafsma, M R; Biemond, B J; Vekemans, M C; Breems, D A; Verdonck, L F; Fey, M F; Jongen-Lavrencic, M; Janssen, J J; Huls, G; Kuball, J; Pabst, T; Graux, C; Schouten, H C; Gratwohl, A; Vellenga, E; Ossenkoppele, G; Löwenberg, B (2015). Comparative therapeutic value of post-remission approaches in patients with acute myeloid leukemia aged 40-60 years. Leukemia, 29(5):1041-1050.
Löwenberg, B; Pabst, T; Vellenga, E; van Putten, W; Schouten, H C; Graux, C; Ferrant, A; Sonneveld, P; Biemond, B J; Gratwohl, A; de Greef, G E; Verdonck, L F; Schaafsma, M R; Gregor, M; Theobald, M; Schanz, U; Maertens, J; Ossenkoppele, G J (2011). Cytarabine dose for acute myeloid leukemia. New England Journal of Medicine, 364(11):1027-1036.
This list was generated on Fri Oct 20 02:07:52 2017 CEST.
